WO2012008733A2 - Cellules souches issues de tissu de placenta primaire et agent thérapeutique contenant celles-ci - Google Patents
Cellules souches issues de tissu de placenta primaire et agent thérapeutique contenant celles-ci Download PDFInfo
- Publication number
- WO2012008733A2 WO2012008733A2 PCT/KR2011/005103 KR2011005103W WO2012008733A2 WO 2012008733 A2 WO2012008733 A2 WO 2012008733A2 KR 2011005103 W KR2011005103 W KR 2011005103W WO 2012008733 A2 WO2012008733 A2 WO 2012008733A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- cells
- derived
- placental tissue
- placental
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 138
- 210000005059 placental tissue Anatomy 0.000 title claims abstract description 110
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 14
- 230000001413 cellular effect Effects 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 47
- 230000004069 differentiation Effects 0.000 claims abstract description 45
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 108010059616 Activins Proteins 0.000 claims abstract description 14
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 101710150336 Protein Rex Proteins 0.000 claims abstract description 13
- 210000003981 ectoderm Anatomy 0.000 claims abstract description 13
- 230000001900 immune effect Effects 0.000 claims abstract description 13
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims abstract description 12
- 210000001900 endoderm Anatomy 0.000 claims abstract description 12
- 230000035755 proliferation Effects 0.000 claims abstract description 12
- 239000000488 activin Substances 0.000 claims abstract description 11
- 230000035935 pregnancy Effects 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 108090001061 Insulin Proteins 0.000 claims abstract description 9
- 229940125396 insulin Drugs 0.000 claims abstract description 9
- 210000003716 mesoderm Anatomy 0.000 claims abstract description 9
- 210000002569 neuron Anatomy 0.000 claims abstract description 9
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims abstract description 8
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims abstract description 8
- 102100025304 Integrin beta-1 Human genes 0.000 claims abstract description 8
- 101100312926 Mus musculus Taf8 gene Proteins 0.000 claims abstract description 8
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims abstract description 7
- 102100022749 Aminopeptidase N Human genes 0.000 claims abstract description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 7
- 102100032912 CD44 antigen Human genes 0.000 claims abstract description 7
- 102100037904 CD9 antigen Human genes 0.000 claims abstract description 7
- 102100037241 Endoglin Human genes 0.000 claims abstract description 7
- 102000006354 HLA-DR Antigens Human genes 0.000 claims abstract description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 claims abstract description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 7
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims abstract description 7
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims abstract description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 7
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims abstract description 7
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims abstract description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 7
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims abstract description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 7
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims abstract description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 7
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 230000014509 gene expression Effects 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 18
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 15
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 15
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 11
- 239000012091 fetal bovine serum Substances 0.000 claims description 11
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 10
- 102000029816 Collagenase Human genes 0.000 claims description 9
- 108060005980 Collagenase Proteins 0.000 claims description 9
- 229960002424 collagenase Drugs 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 208000025966 Neurological disease Diseases 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000003248 secreting effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000036266 weeks of gestation Effects 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 3
- 101100510267 Mus musculus Klf4 gene Proteins 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 230000001582 osteoblastic effect Effects 0.000 claims 1
- 210000004504 adult stem cell Anatomy 0.000 abstract description 16
- 230000004663 cell proliferation Effects 0.000 abstract description 8
- 102000005606 Activins Human genes 0.000 abstract 1
- 102100023915 Insulin Human genes 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 210000004991 placental stem cell Anatomy 0.000 description 39
- 210000001519 tissue Anatomy 0.000 description 31
- 210000002826 placenta Anatomy 0.000 description 29
- 239000002609 medium Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 238000010186 staining Methods 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 10
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 10
- 238000002659 cell therapy Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000010240 RT-PCR analysis Methods 0.000 description 8
- 210000001671 embryonic stem cell Anatomy 0.000 description 8
- 210000004039 endoderm cell Anatomy 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 7
- 230000011164 ossification Effects 0.000 description 7
- -1 Nanog Proteins 0.000 description 6
- 108010088225 Nestin Proteins 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000003169 placental effect Effects 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000012583 B-27 Supplement Substances 0.000 description 4
- 102000008730 Nestin Human genes 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 101150116689 Slc2a2 gene Proteins 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000001705 ectoderm cell Anatomy 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 210000002894 multi-fate stem cell Anatomy 0.000 description 4
- 210000005055 nestin Anatomy 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- WAPPRYMYMNVAFR-UHFFFAOYSA-N 2-sulfanylethanol Chemical compound OCCS.OCCS WAPPRYMYMNVAFR-UHFFFAOYSA-N 0.000 description 2
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 2
- 101150041192 Otx1 gene Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001704 mesoblast Anatomy 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZEQMQPCXFPCFDI-UHFFFAOYSA-N formaldehyde;2-hydroxypropane-1,2,3-tricarboxylic acid;propan-2-one Chemical compound O=C.CC(C)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O ZEQMQPCXFPCFDI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
Definitions
- the present invention relates to adult stem cells derived from first placental tissue of 14 weeks or less in pregnancy, a method of isolating the stem cells, a method of proliferation, and a cell therapeutic agent containing the stem cells.
- Stem cells are cells that have the ability to self-replicate and differentiate into two or more cells, totipotent stem cells, pluripotent stem cells, It can be classified as a multipotent stem cell.
- Pluripotent stem cells are pluripotent cells that can develop into a complete individual. Cells up to 8 cell stages after fertilization of eggs and sperm have this property. Transplantation can result in one complete individual. Pluripotent stem cells are cells that can develop into a variety of cells and tissues derived from ectoderm, mesoderm, and endoderm.Inner cell mass located inside the blastocyst after 4-5 days of fertilization. They are called embryonic stem cells and are differentiated into various other tissue cells but do not form new life. Multipotent stem cells are stem cells that can only differentiate into cells specific to the tissues and organs that contain them.
- the placenta is an organ that occurs in the walls of the uterus when a woman is pregnant, and has a disk-shaped disk-rich form, and the nutrition, respiration, and excretion of the fetus are all made through the placenta.
- the placenta is composed of various types of cells by number of weeks and locations, but its scope of use is extremely limited.
- stem cells derived from conventional placenta were mostly stem cells derived from some tissues of term placenta obtained at birth.
- Korean Patent Application Publication No. 10-2009-7006244 discloses a placenta, its use, and placental stem cells in postpartum mammals, and other published patents are also derived from placental tissue derived stem cells. It is starting.
- the present inventors have isolated and propagated placental stem cells using the first placental placental tissue, and confirmed that these stem cells have superior proliferation rate and differentiation ability as compared with the conventional placental stem cells, and completed the present invention.
- the present invention is characterized in that the first placental tissue less than 14 weeks of gestation of the first trimester treated with collagenase and then cultured in a culture medium containing FGF (Fibroblast Growth Factor) and then recovered, ( a) positive immunological properties for CD9, CD13, CD29, CD44, CD90, CD105 and HLA-Class I and negative immunological properties for CD14, CD19, CD34, CD38, CD45, CD127 and HLA-DR Indicates; (b) expresses genes of Oct4, Nanog, Tbn, Klf4, Activin and Rex1; (c) has the ability to differentiate into ectoderm, mesoderm or endoderm derived cells; And (d) isolating and propagating placental tissue-derived stem cells up to 14 weeks of gestation exhibiting properties that are maintained over 30 passages in an undifferentiated state and the obtained placental tissue-derived stem cells.
- FGF Fibroblast Growth Factor
- the present invention also provides a method for differentiation from the placental stem cells to ectoderm cells, mesoderm cells and endoderm cells.
- the present invention also provides a cell therapy containing the placental stem cells, for example, a cell therapy for the treatment of neurological diseases, bone deletion diseases, and / or diabetes.
- the present invention also provides a method for treating a disease comprising administering the placental stem cells, such as neurological disease, bone deletion disease, and / or diabetes.
- a disease comprising administering the placental stem cells, such as neurological disease, bone deletion disease, and / or diabetes.
- Figure 1 is a photograph of the morphology of the first placental tissue-derived stem cells observed with an optical microscope.
- Figure 2 is a graph showing a comparison of the proliferative power of the placental tissue-derived stem cells and the placenta tissue-derived stem cells of the term (term 3).
- Figure 3 is a result of flow cytometry (FACS analysis) showing the surface expression patterns of stage 1 placental tissue-derived stem cells.
- Figure 4 is the result of observing the increase in the number of cells according to the culture days of the first placental tissue-derived stem cells.
- Figure 5 is a karyotype analysis results by Kimja staining of stem cells derived from the first stage.
- FIG 6 shows the results of reverse transcription polymerase chain reaction (RT-PCR) showing the gene expression patterns of stage 1 placental tissue-derived stem cells (hES: human embryonic stem cell).
- RT-PCR reverse transcription polymerase chain reaction
- FIG. 7 is a PCR result showing the gene expression of stem cells derived from stage 1 placenta and stem cells derived from stage 3 (p5: 5 passages, p15: 15 passages).
- Figure 8 is an immunofluorescence staining (Immunocytochemisty) results showing the gene expression patterns of stage 1 placental tissue-derived stem cells.
- Figure 9 shows immunofluorescence staining (Immunocytochemisty) results showing the nestin gene expression according to ectoderm differentiation of stage 1 placental tissue-derived stem cells and stage 3 placental tissue-derived stem cells.
- Figure 10 is a microscopic picture confirming the differentiation-induced differentiation into ectoderm of the first placental tissue-derived stem cells using immunostaining (A: placental tissue-derived stem cells of undifferentiated, B: placental tissue-derived stem cells into neurons ).
- FIG. 12 is a micrograph showing the differentiation-induced appearance of mesenchymal cells of the first placental tissue-derived stem cells using immunostaining.
- FIG. 13 shows RT-PCR results for differentiated mesodermal cells (Undiff: undifferentiated, Diff: differentiated, Od: 0 days, 11d: 11 days, 13d: 13 days, 15d: 15 days).
- Figure 14 is a micrograph confirming the differentiation induced into endoderm of the first placental tissue-derived stem cells using immunostaining.
- the term 'placenta' consists of a decidual membrane derived from the uterine mucosa of the mother and a chorionic membrane, amnion, etc. derived from the fertilized egg, and is a place where material exchange between the mother and the fetus occurs.
- first trimester placenta' refers to a tissue connected to the fetus and mother of 14 weeks or less, which is the first quarter of pregnancy.
- the second trimester placenta refers to the tissues associated with the fetus and mother, 15-25 weeks, in the second trimester.
- the third trimester placenta refers to the tissues associated with the fetus and the mother, typically 26-40 weeks, the third trimester of pregnancy in which the fetus can be born and survive.
- the term 'stem cell' refers to the undifferentiated cells of the stage before they are differentiated into each cell constituting the tissue, and differentiates into specific cells by specific differentiation stimulation or environment. .
- the term 'embryonic stem cell' refers to any undifferentiated cell derived from an embryo that has the potential to be a variety of specialized cells.
- adult stem cells' used in the present invention refers to stem cells appearing in the stage of development or adult formation of each organ of the embryo.
- Adult stem cells are generally limited to cells that make up a specific tissue.
- progenitor cells' includes not only multipotent undifferentiated cells but also monopotnet undifferentiated cells.
- tissue' refers to a collection of cells having substantially the same function and / or shape in a multicellular organ.
- the origin may be a collection of cells of the same origin or a collection of cells of different origin as long as they have the same function and / or shape.
- the term 'differentiation' refers to a phenomenon in which a structure or a function is specialized while a cell divides and grows, that is, a cell or a tissue of an organism has a shape or function to perform a task given to each. It means to change.
- relatively simple systems are separated into two or more qualitatively different sub systems. For example, qualitatively between parts of a living organism that were almost homogeneous in the first place, such as head or torso distinctions between eggs that were initially homogenous in the development, or cells such as muscle cells or neurons.
- Phosphorus difference or as a result, is a state divided into subclasses or subclasses that can be distinguished qualitatively.
- the term 'cell therapeutic agent' is a medicine (US FDA regulation) used for the purpose of treatment, diagnosis, and prevention of cells and tissues prepared by isolation, culture, and special manufacture from humans, and the function of tissues of cells. It refers to a medicine used for the purpose of treatment, diagnosis, and prevention through a series of actions such as proliferating, selecting, or otherwise changing the biological characteristics of a living autologous, allogeneic or heterologous cell in vitro in order to restore it.
- Cell therapy agents are broadly classified into somatic cell therapy and stem cell therapy according to the degree of differentiation of cells, and the present invention relates in particular to stem cell therapy.
- the present invention relates to a method for separating stem cells from the first placenta (14 weeks or less pregnant), specifically, the treatment of fine placenta tissues less than 14 weeks pregnant with 0.01 ⁇ 0.5% collagenase
- the present invention relates to a method for isolating placental tissue-derived stem cells, which is then cultured in a fibroblast growth factor (FGF) -containing medium and then recovered.
- FGF fibroblast growth factor
- the present invention is the 1 st placental tissue-derived stem cells isolated by the method 2-30% fetal bovine serum (Fetal Bovine Serum, FBS), 2-20 ng / ml fibroblast growth factor and 0.1
- the present invention relates to a method of proliferation of placental tissue-derived stem cells suspended in Dulbecco's Modified Eagle's Media (DMEM) medium containing ⁇ 0.5 mM beta mercaptoethanol ( ⁇ - mercaptoethanol).
- DMEM Dulbecco's Modified Eagle's Media
- the content of the collagenase is 0.01 ⁇ 0.5% (W / V)
- the content of FGF may be characterized in that 2 ⁇ 20 ng / ml
- the placental tissue is 5 weeks or more 7 It may be a mammalian placental tissue of less than a week, the placental tissue may be human-derived placental tissue.
- placental stem cells have been produced with some tissues of term placenta that can be obtained at birth.
- the present invention provides stem cells isolated and cultured in the first placenta, which can be obtained due to the stop of the development of the fetus during pregnancy.
- stem cells unlike differentiated cells in which cell division has stopped, are capable of producing the same cells as themselves by cell division (proliferation; expansion), and when differentiation stimulation is applied It is characterized by having plasticity in differentiation because it can be differentiated into other cells by different environment or differentiation stimulus.
- These stem cells can be divided into embryonic and adult stem cells according to the origin of development, and in the present invention includes both embryonic stem cells and adult stem cells, but preferably means adult stem cells.
- Adult stem cells like embryonic stem cells, are capable of proliferation in a cultured state and have a differentiation ability to develop into cells having characteristic shapes and specialized functions according to changes in culture conditions and culture conditions.
- the adult stem cells can differentiate into tissue-specific progenitor cells inherent in the human body.
- Adult stem cells can be virtually any differentiated cell in the body and have the potential to generate replacement cells for a wide range of tissues and organs such as the heart, pancreas, nerve tissue, muscle, cartilage, and the like.
- Such adult stem cells are obtained from mammalian primates, preferably from most tissues such as human bone marrow, cord blood, blood, fat, liver, skin, gastrointestinal tract, placenta, uterus, brain, pancreas, liver, eyes and fetal tissue.
- the present invention relates to stem cells derived from stage 1 placental tissue, in particular, having differentiation ability into various tissues and having immunomodulatory ability.
- the obtained placental tissues are separated into single cell bodies by treatment with trypsin solution and / or collagenase, and then cultured in a suitable medium in which growth factors such as FGF and EGF are added in an appropriate amount, followed by FACS and the like.
- FGF growth factor
- EGF EGF
- adult stem cells can be isolated according to the growth rate.
- DMEM Dulbecco's Modified Eagle's Media
- ⁇ - mercaptoethanol beta - mercaptoethanol
- non-essential amino acids 1% non-essential amino acids
- antibiotics penicillin / streptomycin
- the finely cut placental tissue is left in a culture dish to induce cells to ooze out of the placental tissue, and after 3-7 days, the remaining placental tissue fragments are removed and attached to the culture dish. Induces them to form cell lines.
- the passage number reaches 30-40. Comparing the cell proliferation rate by separating and culturing cells in the same placenta and tertiary placental tissues, the average number of stem cells derived from tertiary placental tissues showed a sharp increase in the number of passages from 10 to 15 on average. -70 days before and after the life of the cell no longer grows. In comparison with the first placental tissue-derived stem cells according to the present invention shows a steady increase until the passage number 30 ⁇ 40 (120-150 days), and will maintain a steady increase even in more than 40 passages. These results demonstrate that the proliferative power of stage 1 placental tissue-derived stem cells is superior to stage 3 placental tissue-derived stem cells.
- the number and type of proliferated cells can be determined by flow cytometry, cell sorting, immunocytochemistry (eg staining with tissue specific or cell-label specific antibodies), fluorescence activated cell sorting (FACS), Measure changes in morphology and surface labeling of cells using standard cell detection techniques such as magnetic activated cell sorting (MACS), or morphology of cells using optical or confocal microscopy. Or can be easily monitored by measuring changes in gene expression using techniques well known in the art such as PCR and gene expression profiling.
- an antibody that specifically recognizes a surface antigen of a cell is labeled with fluorescence, and the fluorescence intensity is measured by converting the fluorescence intensity into an electrical signal by measuring the fluorescence of a conjugate of the labeled antibody and antigen to quantify the antigen expression level of the cell.
- fluorescent materials to be used it is possible to separate cells expressing a plurality of surface antigens.
- Fluorescent materials usable herein include FITC (fluorescein isothiocyanate), PE (phycoerythrin), APC (allo-phycocyanin), TR (TexasRed), Cy3, CyChrome, Red613, Red670, TRI-Color, QuantumRed and the like.
- the stem cell solution obtained above is collected, and the cells are separated by centrifugation or the like, and then directly stained with an antibody. After culturing and propagating in a medium, the method of staining an antibody can be used. To stain the cells, firstly, the primary antibody recognizing the surface antigen and the desired cell sample are mixed and incubated for 30 minutes to 1 hour on ice. If the primary antibody is labeled with fluorescence, it is separated by a flow cytometer after washing.
- the fluorescently labeled secondary antibody having a binding activity to the primary antibody and the cells reacted with the primary antibody are mixed and incubated in ice water for 30 minutes to 1 hour. After washing, the cells stained with the primary antibody and the secondary antibody are separated by flow cytometry.
- the present invention shows positive immunological properties for (a) CD9, CD13, CD29, CD44, CD90, CD105 and HLA-Class I, obtained by the separation method, and CD14, CD19, CD34, CD38 , Negative immunological properties for CD45, CD127 and HLA-DR; (b) expresses genes of Oct4, Nanog, Tbn, Klf4, Activin and Rex1; (c) has the ability to differentiate into ectoderm, mesoderm or endoderm derived cells; And (d) first placental tissue-derived stem cells of 14 weeks or less in pregnancy, which are characterized by being maintained over 30 passages in an undifferentiated state.
- Adult stem cells derived from the first placental tissue of the present invention are homogeneous, sterile and readily obtained in a form (pharmaceutical grade) suitable for administration to humans. After prolonged incubation, the cells can be characterized with CD series antigen markers such as CD29 (mononuclear cell marker), CD90 (mononuclear stem cell marker) and subjected to FACS analysis.
- CD series antigen markers such as CD29 (mononuclear cell marker), CD90 (mononuclear stem cell marker) and subjected to FACS analysis.
- Preferred placental tissue derived stem cells obtained by the method of the invention can be characterized by the presence of the following cell surface markers: positive immunological for CD9, CD13, CD29, CD44, CD90, CD105 and HLA-Class I Properties, negative immunological properties for CD14, CD19, CD34, CD38, CD45, CD127 and HLA-DR.
- cell surface labels are identified according to methods known in the art, eg, by batch measurements by flow cytometry, followed by washing and staining with anti-cell surface labeling antibodies.
- the placental stem cells of the present invention can also be identified using Oct4 markers, which can be said to be cell markers in undifferentiated state.
- Oct4 is well known as an undifferentiated state marker in stem cells, and in the art, Korean Patent Application No. 10-2004-0105716, "monoclonal antibody specific for human embryonic stem cells", Korean Patent Application No. 10-2004-0096780 "Double-stranded RNA for inhibiting Oct4 gene expression in maintenance of undifferentiated state of mammalian embryos and stem cells," Korean Patent Application No. 10-2006-0092128 As shown in “Cells and Manufacturing Methods", etc., it is common to perform an Oct4 expression test as an experiment for proving that they are stem cells in an undifferentiated state.
- Oct4 by confirming the expression of Nanog, Tbn, Klf4, Activin and Rex1 it can be confirmed that the first placental tissue-derived stem cells according to the present invention has characteristics as stem cells.
- RT-PCR Reverase Transcriptase-Polymerase Chain Reaction
- RT-PCR is a technique for synthesizing a corresponding cDNA using a template of RNA of a specific site, and then PCR amplification using the same, the experimental process (1) using reverse transcriptase It consists of preparing cDNA from RNA and (2) amplifying a specific region using cDNA. (2) process is the same as amplifying a specific gene region from genomic DNA.
- This method is not only simpler than the RNA analysis that was possible through methods such as Northern blot hybridization, but also helps in the study of mRNA sequencing and transcription, since the gene sequence can be determined. Technology is known throughout the industry.
- Stage 1 placental tissue-derived stem cells of the present invention show a positive response to the expression of Oct4, Nanog, Tbn, Klf4, Activin and Rex1 gene markers.
- Oct4 is well known as a marker of undifferentiated state in stem cells, and it is already known in the art that Nanog, Klf4, Activin or Rex1 is also a marker of human stem cells.
- the conventional tertiary placental tissue-derived stem cells were killed without being cultured for more than 20 generations, the first-placed placental tissue-derived stem cells according to the present invention have a proliferative capacity of 30 to 40 generations or more, preferably 40 or more generations.
- the first placental tissue-derived stem cells may be characterized in that the expression level of the Klf4 gene is increased 1.2 to 4 times compared to the third placental tissue-derived stem cells, and the expression level of the Activin gene is increased 1.2 to 4 times. Characterized in that, the expression level of the Rex1 gene may be characterized by an increase of 4 to 8 times. In one embodiment of the present invention, the gene expression capacity was compared in the fifth passage and the 15th passage, but the number of passages increased more than that, it has such excellent expression increase ability even in 30-40 passages or more.
- Early placental stem cells obtained by the method of the present invention have the ability to differentiate into mesoderm, endoderm and ectoderm derived cells. For example, it may be induced to differentiate along specific cell lineages, including beta-pancreatic cell differentiation, osteoblast differentiation, neuronal differentiation.
- the present invention relates to a method of differentiating stage 1 placental stem cells obtained by the isolation and / or proliferation method into ectoderm derived cells, mesodermal derived cells, and / or endoderm derived cells.
- placental stem cells according to the present invention include a method of differentiating neurons, bone cells and insulin secreting pancreatic beta cells.
- Measurement of differentiation of stem cells into specific cell types can be performed by methods well known in the art, for example, (1) placental stem cells are cultured in a medium containing 0.01% to 1% polyethyleneimine Forming a spherical body; And reattaching the globular body to a general culture dish to induce differentiation into neurons, and (2) placenta stem cells to dexamethasone and ascorbic acid-2-phosphate.
- beta-glycophosphate beta-glycophosphate incubated in bone formation induction medium to induce differentiation of placental stem cells into bone formation cells
- placental stem cells N2, B27 supplement and 1 ⁇ Differentiation into insulin-secreting beta-pancreatic cells through culturing in a medium containing 50 ng / ml of bFGF and exchanging the medium with a medium containing N2, B27 supplement and 1-20 mM nicotinamide Can be derived.
- the differentiation may be performed using techniques such as flow cytometry or immunocytochemistry to measure cell surface labels (eg staining cells with tissue-specific or cell-label specific antibodies) and changes in morphology, with optical microscopy. Or by examining the morphology of the cells using confocal microscopy, or by measuring changes in gene expression using techniques well known in the art such as PCR and gene-expression profiles.
- the present invention relates to a cell therapeutic agent containing first stage placental tissue-derived stem cells having the characteristics of differentiating into ectoderm-derived cells, mesoderm-derived cells and / or endoderm-derived cells.
- the present invention is not limited thereto, but as an example, a cell therapeutic agent for treating neurological diseases containing stem cells derived from first placental tissue having the characteristics of differentiating into neurons as an active ingredient, and having the characteristics of differentiating into bone forming cells
- Cell therapy agent for treating bone deletion disease containing stem cell derived from 1st placental tissue as an active ingredient Cell therapy agent for treating diabetes mellitus, containing stem cell derived from 1st placental tissue having the characteristics of differentiating into insulin secreting pancreatic beta cells as an active ingredient
- the stem cells according to the present invention may function as cell therapeutic agents for all diseases that can be treated due to the cells to be differentiated, as described below, due to the trioderm differentiation ability. have.
- Stage 1 placental tissue-derived stem cells according to the present invention can be used for various kinds of treatments, for example, by engraftment, transplantation or infusion of stem cells or derived cell populations.
- the placental stem cells of the present invention can replace or enhance existing tissues, become new or changed tissues, or combine with biological tissues or structures.
- the first placental tissue-derived stem cells of the present invention may be replaced.
- treatment of neurological diseases such as Alzheimer's and Parkinson's disease, muscular diseases such as progressive muscular dystrophy, Lou Gehrig's disease, bone deletion diseases such as osteoarthritis, osteoporosis, and diabetes containing placental stem cells or differentiated cells thereof of the present invention. It can be used for cell therapy.
- the placental stem cells of the present invention are transplanted, for example, of liver, pancreas, kidney, lung, nervous system, muscular system, bone, bone marrow, thymus, spleen, submucosal tissue, gonad or hair. It can be used to enhance or replace stem cells or derived cells.
- placental stem cells of the present invention typically substitute for a specific class of progenitor cells (eg, chondrocytes, stem cells, hematopoietic cells, pancreatic parenchymal cells, neural stem cells, muscle derived cells, etc.) in the therapy in which the derived cells are used. Can be used.
- Placental stem cells of the present invention can be used to strengthen, treat or replace cartilage or ligaments.
- an artificial prosthesis eg, buttock prosthesis
- a joint eg, knee
- Placental stem cells of the present invention can be used to treat tissue and organ damage caused by certain diseases.
- the placenta stem cells may be administered to the patient to regenerate or repair tissues or organs damaged by the disease (eg, to improve the immune system's ability after chemotherapy or radiation, and to repair heart tissue after myocardial infarction). do).
- the cell therapy agent of the present invention can be formulated by methods known to those skilled in the art. For example, it can be used parenterally in the form of an injection as a sterile solution or suspension with water or other pharmaceutically acceptable liquid, if necessary.
- pharmaceutically acceptable carriers or media specifically sterile water or physiological saline, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, excipients, vehicles, preservatives, binders and the like, as appropriately combined
- those formulated by mixing in the form of unit doses required for pharmaceutical implementation are those formulated by mixing in the form of unit doses required for pharmaceutical implementation.
- the amount of the active ingredient should be determined so as to obtain an appropriate dose in a predetermined range, and the sterile composition for injection may be prescribed according to a conventional preparation using a vehicle such as distilled water for injection.
- the placental stem cells of the present invention can also be formulated as injectables (eg, WO 96/39101, incorporated herein by reference).
- aqueous solutions for injection for example, isotonic solutions containing physiological saline, glucose or other adjuvants, such as D-sorbitol, D-mannose, sodium chloride, and suitable dissolution aids such as alcohol, Ethanol, polyalcohols such as propylene glycol, polyethylene glycol, nonionic surfactants such as polysorbate 80 (TM) and HCO-50.
- suitable dissolution aids such as alcohol, Ethanol, polyalcohols such as propylene glycol, polyethylene glycol, nonionic surfactants such as polysorbate 80 (TM) and HCO-50.
- suitable dissolution aids such as alcohol, Ethanol, polyalcohols such as propylene glycol, polyethylene glycol, nonionic surfactants such as polysorbate 80 (TM) and HCO-50.
- buffers such as phosphate buffers, sodium acetate buffers, analgesics such as procaine hydrochloride, stabilizers such as benzyl alcohol, phenols, antioxidants.
- analgesics such as procaine hydrochloride
- stabilizers such as benzyl alcohol, phenols, antioxidants.
- Administration into the patient's body is preferably parenteral administration, specifically, once administration to the damaged area is basic, but may be administered several times.
- the administration time may be a short time or a long time continuous administration. More specifically, there may be mentioned injection, transdermal administration and the like.
- the first placenta was successfully implanted after embryo transplantation at the Maria Infertility Hospital, according to the guidelines of the Institutional Review Board of the Maria Infertility Hospital. However, since the heart was stopped due to ultrasonography, it was collected. It was used for research. Separated in aseptic condition and transferred to the laboratory.
- DPBS Dulbecco's Phosphate Buffered Saline
- Washed cells were treated with 10% Fetal Bovine Serum (FBS), 4 ng / ml fibroblast growth factor (FGF), 0.1 mM beta-mercaptoethanol ( ⁇ - mercaptoethanol), and 1% non-essential amino acids (non- Incubated in Dulbecco's Modified Eagle's Media (DMEM) medium containing essential amino acids) and antibiotics (penicillin / streptomycin), and cultured in a humidified chamber at 37 ° C. and 5% CO 2 .
- FBS Fetal Bovine Serum
- FGF fibroblast growth factor
- ⁇ - mercaptoethanol beta-mercaptoethanol
- 1% non-essential amino acids non- Incubated in Dulbecco's Modified Eagle's Media (DMEM) medium containing essential amino acids
- antibiotics penicillin / streptomycin
- the isolated cells removed the non-adherent tissue debris after 5 days of medium exchange. When the cells proliferated and became denser on the culture surface (75 cm 2 ), they were almost full (passfluent 1).
- the finely cut placental tissue is left in a culture dish to induce cells to seep out of the placental tissue, and after 3-7 days, the remaining placental tissue fragments are removed and the cells growing on the petri dish are allowed to grow. Induced to form cell lines (FIG. 1).
- the proliferation rate of the isolated human stage 1 placental stem cells was investigated. Human stage 1 placental stem cell lines were cultured up to 90-150 days after culturing 16 cell lines, and compared to the term (term 3) placenta-derived stem cell proliferation rate obtained at the time of delivery, which was also reported in cell proliferation rate. Higher results.
- Cells were harvested with PBS with 2 mM EDTA / 5% FBS and washed twice with PBS to analyze surface antigens of human stage 1 placental stem cells. Subsequently, fluorescein isothiocyanate (FITC) or PE (phycoerythrin) bound antibody was added to the cell suspension in an appropriate ratio in 2% FBS / PBS buffer and treated at 4 ° C. for 30 minutes, followed by FACS Vantage SE (Becton & Dickson). The fluorescence of the cells was measured. 5 ⁇ g / ml of propidium iodide was added to remove dead cells and debris prior to analysis. The results obtained were analyzed using the CellQuest (Becton & Dickinson) program.
- FITC fluorescein isothiocyanate
- PE phycoerythrin
- Example 6 karyotyping of stem cells derived from placental tissue
- the first placental stem cells with about 70% confluence in a 100 mm culture dish were treated with 0.1 ⁇ g / ml of colcemid for 2 hours, collected, washed and 75 mM potassium chloride at 37 ° C. The solution was treated for 20 minutes. After the treatment, the stock solution was washed by centrifugation, and then fixed with a fixed solution mixed with methanol and acetic acid (3: 1).
- the fixed cells were centrifuged again and resuspended in 0.5 ml of the same fixed solution.
- One drop of the suspension was dropped on a slide at a height of 30 cm. After the sample was completely dried, the slides were treated with 0.025% trypsin for 30 seconds and again washed with PBS. Samples were stained with 10% Giemsa solution and subjected to karyotyping with Cytovision of Applied Imaging.
- the results are shown in FIGS. 4 and 5.
- the established stage 1 placental stem cells proliferated continuously without any visible karyotype or morphological changes in vitro for 90-150 days.
- RT-PCR analysis was performed on the Klf4, Activin, and Rex1 genes of the cells by separating and culturing cells in the placental and tertiary placental tissues in the same manner.
- Target sequences from cDNA were amplified using the I-taq premix kit (Invitron Biotechnology) under the following conditions. The denatured cDNA was amplified for 35 minutes at 95 ° C, then denatured at 95 ° C for 30 seconds, then annealed at 60 ° C for 45 seconds, and amplified at 72 ° C for 45 seconds. It was. Amplified cDNA was identified by separation on 1.2% agarose gel and stained with ethidium bromide. When loading the amplified cDNA, the pixel intensity of GAPDH expression was normalized to cDNA amount of each experimental group.
- the first placental tissue-derived stem cells are expressed in Oct4, Nanog, Tbn, Klf4, Activin genes expressed in embryo-associated tissues or cells, the immunofluorescence staining results are shown in Figure 8 As shown.
- the expression levels of Klf4, Activin and Rex1 genes in expression genes are significantly higher in first placental tissue-derived stem cells than in third placental stem cells. This may be associated with differentiation and proliferation (FIG. 7).
- RT-PCR analysis was performed on the nestin gene of cells by separating and culturing cells in the first place and the third placenta tissue.
- stage 1 placental tissue had an initial nestin expression of 30.4%, which is significantly lower than that of cells derived from stage 3 placental. This suggests that cells derived from the stage 1 placenta are much more immature and can be said to agree with the above results.
- the starter group was more homogenous and more capable of differentiation than the 3rd cell differentiation rate of 91.7%. It can be confirmed (FIG. 9).
- Human placenta derived stem cells established in Example 3 were cultured in a culture dish coated with 0.01-1% polyetherenimine in an amount of 0.2 ⁇ 10 5 to 2.5 ⁇ 10 5 per cm 2. On day 2, stem cells in each culture dish aggregated with each other without adhering to the culture dish surface to form spheroids. This spherical body is reattached to a general culture dish to induce differentiation.
- Differentiation-induced cells were transferred onto a cover slip, incubated for 2 to 3 days, fixed with 4% paraformaldehyde solution at room temperature for 15 minutes, and washed with PBS.
- the fixed cells were diluted in PBS solution containing 5-10% Triton X-100 and normal goat serum at the rate indicated by the antibody producer, added to the sample, and then at room temperature. The reaction was carried out overnight at 1 hour or in a cold state.
- TRITC tetrarhodamine isothiocyanate
- FITC conjugate was reacted with primary antibody at room temperature or in a cold state. Treated in the same way.
- the cell nuclei were stained with Hoechst 33342 (10 ⁇ g / ml, Sigma) and observed by fluorescence microscopy.
- FIG. 10A shows undifferentiated stage 1 placental derived stem cells
- FIG. 10 B is a photograph showing stage 1 placental stem cells differentiated into neural progenitor cells showing Nestin expression.
- RT-PCR analysis was performed on Otx1 and NeuroD genes with the cells differentiated into ectoderm cells. The analysis was performed in the same manner as the reverse transcription polymerase chain reaction described in Example 7.
- stage 1 placental stem cells were induced to differentiate into ectoderm cells.
- Human stage 1 placenta-derived stem cells established in Example 3 were collected at a density of 0.1 ⁇ 10 4 to 1 ⁇ 10 4 per cm 2 (0.1 ⁇ mol / l dexamethasone, 0.05 mmol / l ascorbic acid-2-phosphate, 10 mmol / l beta-glycophosphate (20% human serum) for 10-21 days. After differentiation, Alizarin Red S staining and Alkaline phosphatase (ALP) staining confirmed the differentiation of placental stem cells into mesodermal cells related to bone formation.
- ALP Alkaline phosphatase
- alkaline phosphatase activity as a bone differentiation marker by staining
- cells differentiated from bone formation differentiation medium were cultured on a chamber slide, washed with sterile tertiary distilled water, and then ALP staining kit (Sigma-Aldrich, Steinheim). , Germany). Immersion was fixed in Citrate-Acetone-Formaldehyde fixative for 30 seconds and washed with deionized water. Slides were incubated for 15 minutes at room temperature in alkaline dye mixture, washed again, and stained with Neutral Red solution.
- the degree of ALP staining and Alizarin Red S staining can be confirmed that compared to the undifferentiated stem cells, it was confirmed that differentiation into mesodermal cells related to bone formation.
- RT-PCR analysis was performed on BGP, ALP, and ColiaI genes with the cells differentiated into mesodermal cells. RT-PCR was analyzed by the same process as the reverse transcription polymerization reaction described in Example 7.
- the cells began to differentiate and showed expression of genes related to bone formation such as BGP, ALP, Colia1 from 10 days to 21 days. These results show that human placental stem cells can differentiate into mesodermal cells related to bone formation.
- Human placenta-derived stem cells established in Example 3 were endothelial differentiation-inducing medium (ES-Cult basal containing N2 and B27 supplement and 10-25 ng / ml bFGF) at a concentration of 0.3 ⁇ 10 4 to 4 ⁇ 10 4 / cm 2. medium) and incubated for 6-7 days and exchanged for endoderm differentiation maturation medium (ES-Cult basal medium containing N2, B27 supplement and 10 mM nicotinamide) for 6-7 days.
- endothelial differentiation-inducing medium ES-Cult basal containing N2 and B27 supplement and 10-25 ng / ml bFGF
- endoderm differentiation maturation medium ES-Cult basal medium containing N2, B27 supplement and 10 mM nicotinamide
- Immunostaining assays were performed for Glut2, Insulin antibodies using the cells differentiated into endoderm cells. Immunostaining was analyzed in the same manner as the immunostaining assay mentioned in Example 6.
- RT-PCR analysis was performed on the Glut2 and Glucagon genes with the cells differentiated into endoderm cells. RT-PCR was analyzed in the same manner as the reverse transcription polymerase chain reaction described in Example 7.
- Glut2 and Glucagon were confirmed by differentiation of placental stem cells to confirm that they differentiated into true endoderm cells.
- the placental tissue-derived adult stem cells according to the present invention are very useful as cell therapeutic agents because they have excellent cell proliferation rate and more favorable differentiation ability than the existing placental tissue-derived stem cells. .
- it has the ability to differentiate into neural cells, bone forming cells or insulin secreting pancreatic beta cells, and is effective in the treatment of bone deletion diseases, neurological diseases, diabetes and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des cellules couches issues de tissu de placenta primaire à 14 semaines ou moins de gestation, un procédé de séparation de ces cellules, un procédé permettant la prolifération de celles-ci et un agent thérapeutique cellulaire contenant ces cellules souches. Plus particulièrement, l'invention concerne des cellules souches issues de tissu de placenta primaire à 14 semaines ou moins de gestation, un procédé de séparation de ces cellules, un procédé permettant la prolifération de celles-ci et un agent thérapeutique cellulaire contenant ces cellules souches, lesdites cellules souches (a) possédant des propriétés immunologiques positives par rapport à CD9, CD13, CD29, CD44, CD90, CD105 et le système HLA de classe I, et des propriétés immunologiques négatives contre CD14, CD19, CD34, CD38, CD45, CD127 et le système HLA-DR; (b) exprimant les gènes Oct4, Nanog, Tbn, Klf4, d'activine et Rex1; (c) étant capables de se différencier en cellules issues de l'ectoderme, du mésoderme ou de l'endoderme; et étant maintenues pendant 30 générations ou plus dans un état indifférencié. Bien qu'étant des cellules souches adultes, les cellules souches de l'invention issues de tissu de placenta primaire présentent une excellente capacité de prolifération cellulaire et une capacité de différenciation avantageuse par rapport à des cellules souches existantes issues de tissu de placenta primaire, et peuvent par conséquent être utilisées efficacement comme agent thérapeutique cellulaire. En particulier, ces cellules souches peuvent se différencier en cellules nerveuses, en cellules ostéogènes ou en cellules pancréatiques bêta sécrétant de l'insuline, et sont également efficaces pour traiter des maladies de déficit osseux, des maladies nerveuses, le diabète, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0067086 | 2010-07-12 | ||
| KR1020100067086A KR20120006386A (ko) | 2010-07-12 | 2010-07-12 | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012008733A2 true WO2012008733A2 (fr) | 2012-01-19 |
| WO2012008733A3 WO2012008733A3 (fr) | 2012-04-19 |
Family
ID=45469910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2011/005103 WO2012008733A2 (fr) | 2010-07-12 | 2011-07-12 | Cellules souches issues de tissu de placenta primaire et agent thérapeutique contenant celles-ci |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20120006386A (fr) |
| WO (1) | WO2012008733A2 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10232000B2 (en) | 2014-01-08 | 2019-03-19 | Samsung Life Public Welfare Foundation | Stem cells derived from basal portion of chorionic trophoblast layer and cell therapy comprising same |
| WO2019125073A1 (fr) * | 2017-12-22 | 2019-06-27 | 고려대학교 산학협력단 | Milieu conditionné par des cellules dérivées du placenta pour l'induction d'une dédifférenciation à partir de cellules somatiques donnant des cellules souches pluripotentes induites et procédé d'induction d'une dédifférenciation l'utilisant |
| WO2020036245A1 (fr) * | 2018-08-17 | 2020-02-20 | 고려대학교 산학협력단 | Milieu conditionné de cellules dérivées du placenta pour la production et l'amélioration de la fonction de cellules souches neurales humaines, et utilisation associée |
| US10617721B2 (en) | 2013-10-24 | 2020-04-14 | Ospedale San Raffaele S.R.L. | Methods for genetic modification of stem cells |
| US10669526B2 (en) | 2014-01-08 | 2020-06-02 | Samsung Life Public Welfare Foundation | Stem cells derived from pure chorionic trophoblast layer and cell therapy comprising same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102317052B1 (ko) * | 2020-05-04 | 2021-10-25 | 주식회사 티에스셀바이오 | 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물 |
-
2010
- 2010-07-12 KR KR1020100067086A patent/KR20120006386A/ko not_active Ceased
-
2011
- 2011-07-12 WO PCT/KR2011/005103 patent/WO2012008733A2/fr active Application Filing
Non-Patent Citations (3)
| Title |
|---|
| BATTULA ET AL.: 'Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation' DIFFERENTIATION vol. 75, 2007, pages 279 - 291 * |
| MIAO ET AL.: 'Isoration of mesenchymal stem cells from human placenta: Comparison with human bone marrow mesenchymal stem cells' CELL BIOLOGY INTERNATIONAL vol. 30, 2006, pages 681 - 687 * |
| PORTMANN-LANZ ET AL.: 'Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration' AMERICAN vol. 194, 2006, pages 664 - 673 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617721B2 (en) | 2013-10-24 | 2020-04-14 | Ospedale San Raffaele S.R.L. | Methods for genetic modification of stem cells |
| US10232000B2 (en) | 2014-01-08 | 2019-03-19 | Samsung Life Public Welfare Foundation | Stem cells derived from basal portion of chorionic trophoblast layer and cell therapy comprising same |
| US10669526B2 (en) | 2014-01-08 | 2020-06-02 | Samsung Life Public Welfare Foundation | Stem cells derived from pure chorionic trophoblast layer and cell therapy comprising same |
| WO2019125073A1 (fr) * | 2017-12-22 | 2019-06-27 | 고려대학교 산학협력단 | Milieu conditionné par des cellules dérivées du placenta pour l'induction d'une dédifférenciation à partir de cellules somatiques donnant des cellules souches pluripotentes induites et procédé d'induction d'une dédifférenciation l'utilisant |
| WO2020036245A1 (fr) * | 2018-08-17 | 2020-02-20 | 고려대학교 산학협력단 | Milieu conditionné de cellules dérivées du placenta pour la production et l'amélioration de la fonction de cellules souches neurales humaines, et utilisation associée |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120006386A (ko) | 2012-01-18 |
| WO2012008733A3 (fr) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022046511A (ja) | 胎盤幹細胞を使用する免疫調節 | |
| Fauza | Amniotic fluid and placental stem cells | |
| WO2015105356A1 (fr) | Cellules souches dérivées d'une couche trophoblastique chorionique pure, et thérapie cellulaire comprenant celles-ci | |
| WO2011049414A2 (fr) | Procédé pour l'induction d'une migration de cellules souches adultes dérivées de tissu adipeux | |
| WO2012008733A2 (fr) | Cellules souches issues de tissu de placenta primaire et agent thérapeutique contenant celles-ci | |
| WO2015105357A1 (fr) | Cellules souches dérivées de la partie basale de la couche trophoblastique chorionique, et thérapie cellulaire comprenant celles-ci | |
| WO2021118226A1 (fr) | Procédé de préparation d'une cellule souche mésenchymateuse à partir d'une cellule souche pluripotente humaine et cellules souches mésenchymateuses ainsi préparées | |
| WO2019103528A2 (fr) | Composition de milieu de culture asérique | |
| WO2013085303A1 (fr) | Cellules souches multipotentes dérivées de la membrane amniotique canine | |
| WO2012173358A2 (fr) | Cellules souches pluripotentes issues de cellules somatiques du testicule, procédé de production de celles-ci, et composition pharmaceutique pour le traitement de l'impuissance comprenant celles-ci | |
| WO2012033352A2 (fr) | Cellules souches multipotentes dérivées du liquide amniotique équin et leur procédé de production | |
| WO2011102680A9 (fr) | Antigène cd49f favorisant la prolifération, la pluripotence et la reprogrammation de cellules souches adultes par l'intermédiaire de la voie pi3k/akt/gsk3 | |
| WO2013165120A1 (fr) | Procédé pour cultiver des cellules souches de crête neurale, et utilisation de celles-ci | |
| WO2019198962A1 (fr) | Procédé pour favoriser la prolifération et la différenciation de cellules souches pluripotentes induites préparées à partir de cellules souches issues d'urine | |
| WO2011126177A1 (fr) | Procédé d'augmentation de l'activité dans des cellules souches humaines | |
| WO2019050350A2 (fr) | Cellule de type de sertoli dérivée de cellule souche procédé de préparation associé et utilisation associée | |
| WO2021096218A1 (fr) | Procédé d'isolement de culture pure de cellules endothéliales vasculaires, milieu de maintien des caractéristiques de cellules endothéliales vasculaires, et procédé de culture le comprenant | |
| WO2022004938A1 (fr) | Procédé de préparation de cellules souches de type mésenchymateuses | |
| WO2013077639A1 (fr) | Cellules souches mésenchymateuses issues d'une membrane amniotique équine | |
| WO2013108949A1 (fr) | Procédé de préparation de cellules progénitrices périvasculaires dérivées de cellules souches embryonnaires et composition pour thérapie cellulaire les contenant | |
| WO2010008157A2 (fr) | Procédé permettant de différencier des cellules souches de cellules ectodermiques | |
| WO2022108165A1 (fr) | Procédé de production d'exosomes isolés à partir de cellules souches mésenchymateuses dérivées de cellules souches pluripotentes induites, et utilisation associée | |
| WO2017039251A1 (fr) | Cellule adhérente postnatale améliorée, et utilisation de celle-ci | |
| WO2018101723A1 (fr) | Nouvelles cellules progénitrices mésenchymateuses fonctionnellement améliorées, composition d'agent thérapeutique cellulaire anti-inflammatoire les contenant, et procédé de préparation de cellules progénitrices mésenchymateuses | |
| WO2019221477A1 (fr) | Composition pour favoriser la différenciation de cellules souches, comprenant une solution de culture de cellules progénitrices et un film de graphène multicouche, et son utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11807018 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11807018 Country of ref document: EP Kind code of ref document: A2 |